Last reviewed · How we verify
Continuous Perineural Ropivicaine Infusion
At a glance
| Generic name | Continuous Perineural Ropivicaine Infusion |
|---|---|
| Sponsor | Eric Shepard |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks (PHASE4)
- Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks (PHASE4)
- Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks (PHASE4)
- Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study (PHASE4)
- Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty (PHASE4)
- Effects of Catheter Tip Location Relative to the Femoral Nerve on Sensory and Motor Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Perineural Ropivicaine Infusion CI brief — competitive landscape report
- Continuous Perineural Ropivicaine Infusion updates RSS · CI watch RSS
- Eric Shepard portfolio CI